Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q86V25

UPID:
VASH2_HUMAN

ALTERNATIVE NAMES:
Vasohibin-2; Vasohibin-like protein

ALTERNATIVE UPACC:
Q86V25; B4DYZ5; Q2VT46; Q5VTE7; Q5VTE9; Q7Z6E3; Q8IZ24; Q9H9W5

BACKGROUND:
The protein Tubulinyl-Tyr carboxypeptidase 2, with alternative names Vasohibin-2 and Vasohibin-like protein, is integral to the regulation of microtubule dynamics by detaching the C-terminal tyrosine residue from alpha-tubulin. Its significance extends to ensuring the fidelity of chromosome segregation during mitosis by influencing spindle function. It also serves as an angiogenesis activator in mononuclear cells involved in new blood vessel formation and plays a role in the development of axons.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Tubulinyl-Tyr carboxypeptidase 2 holds promise for unveiling novel therapeutic avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.